Candiduria: Causes, Symptoms, and Treatment

Candiduria refers to the presence of Candida yeast in the urine, and in most cases it signals colonization rather than a true infection requiring treatment. This is one of the central frustrations of the condition: a positive urine culture showing Candida often leaves clinicians uncertain about whether to act on the result or simply remove a urinary catheter and wait. The distinction between harmless colonization and dangerous infection depends heavily on the patient’s overall health, their risk factors, and whether they have symptoms, making candiduria one of the more nuanced problems in infectious disease.

Why Candida Ends Up in the Urinary Tract

Candida species are commensal organisms, meaning they live on and in the human body without causing harm under normal conditions. They inhabit the skin, mouth, gastrointestinal tract, and genital mucosa. The urinary tract is not their usual home, so when Candida appears in urine, something has changed in the patient’s physiology or their clinical environment to let the yeast gain a foothold.

The single most important risk factor is an indwelling urinary catheter. A catheter provides a physical surface for Candida to adhere to and form a biofilm, a dense community of yeast cells embedded in a protective matrix that shields them from antifungal drugs and the immune system. In one study of catheterized patients with hospital-acquired urinary tract infections, about a quarter of cases were caused by Candida species, and over half of those isolates produced biofilm.¹ Animal models have confirmed this mechanism: Candida proliferates as biofilm on the catheter surface and continuously sheds yeast cells into the urine, producing persistent candiduria and inflammation.²

Beyond catheters, diabetes is a major predisposing condition. High blood sugar, glucose spilling into the urine, and poor glycemic control all create an environment where Candida thrives. Research in diabetic patients has found that elevated fasting blood sugar, the presence of glucose in the urine, and an HbA1c above 8 percent are each independently linked to candiduria.³ Broad-spectrum antibiotics also contribute by wiping out the normal bacterial flora that ordinarily keeps Candida populations in check. Other well-recognized risk factors include immunosuppression from drugs or disease, prolonged hospitalization, and extremes of age.

Candida can reach the urinary tract through two routes. The ascending route is more common: yeast from the perineum or genital area travels upward, particularly along a catheter, into the bladder. Less frequently, Candida reaches the kidneys through the bloodstream during an episode of candidemia, seeding the renal tissue from above and then appearing in the urine. This hematogenous route is the more dangerous scenario because it implies systemic infection.

Which Candida Species Are Involved

Candida albicans remains the most frequently isolated species in candiduria, accounting for roughly half of cases across multiple studies.⁴ But the proportion of non-albicans species has been climbing, and this shift matters because several of those species carry intrinsic resistance to common antifungal drugs.

The non-albicans species most commonly found in urine include Candida tropicalis, Candida glabrata, and Candida krusei. In diabetic patients specifically, C. glabrata can be especially prominent, appearing in more than a third of candiduria cases in one study of that population.⁵ C. krusei is inherently resistant to fluconazole, the first-line antifungal for urinary Candida infections, which makes species identification genuinely important rather than academic. When susceptibility testing was performed on a large batch of clinical Candida isolates from a tertiary care hospital, all were sensitive to amphotericin B and voriconazole, but about a third showed resistance to itraconazole and roughly 20 percent had acquired fluconazole resistance, with an additional 20 percent intrinsically resistant.⁴

Candida auris deserves separate mention. This species has emerged as a serious hospital-associated pathogen over the past decade, with high rates of multidrug resistance and an unusual ability to persist on surfaces and spread between patients. Hospitals have been urged to develop specific prevention and control policies for C. auris infections, including urinary isolates.

Symptoms, or the Lack of Them

The most common presentation of candiduria is no symptoms at all. The yeast is found incidentally on a urine culture ordered for another reason, often in a catheterized hospital patient. This asymptomatic colonization is, by a wide margin, the most frequent scenario. And it is precisely this silence that makes the finding confusing: a lab report showing Candida in the urine can look alarming on paper even when it reflects nothing clinically significant.

When candiduria does produce symptoms, they resemble those of a bacterial urinary tract infection: burning or pain with urination, increased frequency and urgency, cloudy or foul-smelling urine, and lower abdominal discomfort. In patients with upper tract involvement, flank pain and fever suggest that the infection has reached the kidneys. However, many of these signs overlap with other conditions, and in catheterized patients the catheter itself can cause irritation and pyuria (white blood cells in the urine) independent of any infection.

Distinguishing true Candida cystitis from colonization is one of the persistent headaches of managing candiduria. Pyuria, a finding clinicians often rely on to confirm infection, is nonspecific in this context. Colony counts on urine culture, which are useful for diagnosing bacterial urinary tract infections, have not proven diagnostically useful for Candida.⁶ There is no clean threshold of yeast colony counts that reliably separates colonization from infection. Clinicians instead rely on the overall clinical picture: is the patient symptomatic? Are they immunocompromised? Do they have a catheter? Is there anatomic abnormality in the urinary tract?

One rare but definitive finding is the presence of Candida casts in the urine, which indicate that the infection involves the kidney parenchyma. These are almost never seen, but when they appear, they confirm renal candidiasis.⁶

When Not to Treat

This is perhaps the most counterintuitive aspect of candiduria for patients and even for some clinicians: the standard recommendation for asymptomatic candiduria is not to prescribe antifungals. Guidelines consistently advise against treating asymptomatic candiduria and instead recommend addressing the underlying risk factors, particularly removing or replacing the urinary catheter.⁷ Treating colonization with antifungals while a catheter remains in place is discouraged because it can promote the emergence of drug-resistant organisms without clearing the yeast.⁸

Despite these guidelines, overtreatment is common. A multi-institutional study found that hospitalized patients with asymptomatic candiduria frequently receive antifungal therapy they do not need.⁷ The instinct to treat a positive culture is strong, but in this setting, restraint is the evidence-based approach for the majority of patients. Simply removing the catheter resolves the candiduria in many cases without any antifungal at all.

There are exceptions. Patients about to undergo urologic procedures, those who are neutropenic, and very low birth weight neonates should be treated even if asymptomatic, because the risk of the yeast disseminating into the bloodstream is too high to ignore in these groups.

When Treatment Is Warranted and What to Use

For patients with symptomatic Candida cystitis, fluconazole is the preferred antifungal. It reaches high concentrations in the urine because it is primarily excreted by the kidneys, it is available in both oral and intravenous forms, and it has a favorable safety profile.⁹ A typical course for uncomplicated Candida cystitis is 200 mg daily for two weeks, though dosing depends on the species identified and the patient’s kidney function.

Flucytosine is another drug that concentrates well in urine and has broad activity against Candida species, but its use requires caution because of potential bone marrow toxicity and gastrointestinal side effects.⁹ It is sometimes used in combination with amphotericin B for resistant infections or renal involvement.

The echinocandin class of antifungals, which includes caspofungin and micafungin, presents an interesting pharmacological puzzle. These drugs achieve very low concentrations in urine because they are metabolized by the liver rather than excreted through the kidneys. On paper, this should make them poor choices for urinary tract infections. In practice, case reports and small series have documented successful treatment of Candida urinary infections with echinocandins, likely because the drugs reach adequate concentrations in the kidney tissue and bladder wall even without appearing in the urine itself.¹⁰ This matters most for infections caused by fluconazole-resistant species, where clinicians may have limited options.

Amphotericin B bladder irrigation is a more targeted approach, involving instilling the drug directly into the bladder through a catheter. A systematic review with meta-analysis found that continuous bladder irrigation with amphotericin B cleared candiduria in about 82 percent of patients within 24 hours, and that extending the irrigation beyond five days improved sustained clearance compared to shorter courses.¹¹ Fluconazole irrigation has also been used successfully to eliminate catheter-associated candiduria without requiring catheter removal.¹² Bladder irrigation is most useful in patients who cannot tolerate systemic antifungals or whose candiduria is clearly localized to the bladder.

Fungal Balls and Urinary Obstruction

One of the more dramatic complications of candiduria is the formation of fungal bezoars, sometimes called fungal balls. These are dense masses of Candida hyphae and debris that can form anywhere along the urinary tract: in the renal pelvis, the ureters, or the bladder. They occur almost exclusively in immunocompromised patients and can grow large enough to obstruct urine flow, causing hydronephrosis, acute kidney injury, or complete inability to urinate.¹³

Treatment of fungal bezoars requires relieving the obstruction, usually with nephrostomy tubes or ureteral stents, combined with antifungal therapy. In one reported case, a patient with extensive fungal bezoars caused by Candida tropicalis in both kidneys, both ureters, and the bladder was treated with bilateral ureteral stenting and three weeks of fluconazole; follow-up ureteroscopy confirmed complete eradication.¹³ Surgical removal of fungal balls is sometimes necessary but carries its own risks, and a review of published cases has suggested that medical management with antifungals and drainage is not inferior to operative intervention.¹⁴ The complication is further aggravated when C. glabrata is the culprit, because this species often resists the azole drugs and may require amphotericin B.¹⁴

Candiduria in the ICU

Candiduria takes on different significance in critically ill patients. In the intensive care unit, the concern is less about the urinary tract itself and more about what the finding signals. In some ICU patients, Candida in the urine is the first detectable sign of systemic Candida infection, candidemia, which carries substantial mortality. The relationship between candiduria and candidemia has been described as significant, with mortality in some affected ICU patients reaching as high as 50 percent.¹⁵

The challenge is that most ICU patients with candiduria still do not have bloodstream infection. Treating every case would mean massive overuse of antifungals in a population already at high risk for drug-resistant infections. The general consensus is that urinary candidiasis in critically ill patients should be treated as a risk factor for invasive disease rather than a standalone diagnosis, and that antifungal treatment should be strongly considered when candiduria appears alongside other risk factors for dissemination, such as heavy Candida colonization at multiple body sites, recent abdominal surgery, or hemodynamic instability.¹⁶ Distinguishing the ICU patient who needs treatment from the one who can safely be observed remains one of the harder judgment calls in critical care infectious disease.

Candiduria in Newborns and Renal Transplant Recipients

Two other populations deserve specific attention because candiduria behaves differently in each.

In extremely low birth weight neonates, those born weighing under 1,000 grams, candiduria should always prompt a full workup for disseminated Candida infection and immediate initiation of antifungal treatment. These infants are at substantial risk for death or neurodevelopmental impairment from Candida infections, and the threshold for concern is much lower than in adults.¹⁷ In this population, a positive urine culture is not something to watch and wait on.

Renal transplant recipients are another group where candiduria is common and concerning, though the appropriate management response is less clear-cut. A large study of transplant patients found that candiduria was associated with reduced survival, but treatment of asymptomatic candiduria did not improve outcomes.¹⁸ In other words, the candiduria appeared to be a marker for how sick the patient was overall rather than a treatable cause of poor outcomes. Removal of the bladder catheter within a week of diagnosis was common, and candiduria cleared in about three-quarters of cases.¹⁸ The emphasis in transplant patients, as in others, remains on reducing modifiable risk factors: removing catheters promptly, improving glycemic control, and being judicious with antibiotics.

Biofilm and Why Catheter-Related Candiduria Resists Treatment

If you have ever wondered why candiduria so often recurs in catheterized patients even after antifungal therapy, biofilm is the answer. When Candida attaches to a catheter surface, it transitions from free-floating yeast cells into an organized community encased in a sticky extracellular matrix. Cells within this biofilm behave differently from their planktonic counterparts: they grow more slowly, communicate chemically with neighboring cells, and display dramatically increased tolerance to antifungal drugs.²

Non-albicans Candida species appear to be especially prolific biofilm producers. In one analysis, biofilm formation was found in about 63 percent of non-albicans isolates compared to 40 percent of C. albicans isolates from catheter-associated infections.¹ This is one of the practical reasons why catheter removal, rather than antifungal escalation, is considered the most effective first step in managing catheter-associated candiduria. You can pour drugs into the system, but as long as the biofilm-coated catheter stays in place, it continues to seed yeast into the urine.

SGLT2 Inhibitors and a Newer Risk Factor

A class of diabetes medications called SGLT2 inhibitors, which includes drugs like empagliflozin, dapagliflozin, and canagliflozin, works by preventing the kidneys from reabsorbing glucose, so excess sugar is excreted in the urine. This mechanism is effective for blood sugar control but creates an environment in the urinary tract that Candida finds hospitable. Genital yeast infections are a well-known side effect of these drugs, and there is growing concern that they may also contribute to more severe Candida urinary tract infections. For patients on SGLT2 inhibitors who develop recurrent candiduria, clinicians may need to weigh the metabolic benefits of the medication against the urinary risk.

The Diagnostic Gray Zone

One of the things that makes candiduria frustrating for patients and clinicians alike is the lack of a sharp diagnostic line between colonization and infection. With bacterial urinary tract infections, colony counts on culture help stratify risk: above a certain threshold, infection is likely. That approach does not work for Candida. Even very high colony counts can represent colonization rather than tissue invasion, and low counts do not rule out infection in an immunocompromised host.⁶

Newer laboratory tools are being explored to help, particularly for detecting invasive Candida disease. Beta-1,3-D-glucan (BDG) testing, which detects a component of the fungal cell wall in blood, has shown better sensitivity than PCR-based testing for identifying candidemia, particularly in ICU patients.¹⁹ These tests are primarily used for bloodstream infections rather than urinary infections specifically, but in the ICU patient with candiduria where the key question is “has this disseminated?”, a positive BDG test can tip the clinical decision toward treatment. The diagnostic landscape remains imperfect, however, and clinical judgment continues to carry most of the weight in deciding who gets treated.

Microscopy can sometimes offer a clue. The morphology of the yeast seen under the microscope can help differentiate C. glabrata, which appears as small round cells without the pseudohyphae seen in C. albicans, offering an early hint about which species is responsible before formal culture results return.⁶ This is useful because it can guide empiric therapy: if a clinician suspects C. glabrata or C. krusei, they may choose to avoid fluconazole and reach for amphotericin B or an echinocandin instead.

1
PubMed Central. Candiduria in Catheter Associated Urinary Tract Infection with Special Reference to Biofilm Production
2
PubMed Central. Rat indwelling urinary catheter model of Candida albicans biofilm infection
3
PubMed Central. Characterization and identification of candiduria due to Candida species in diabetic patients
4
PubMed Central. Species Distribution and Antifungal Susceptibility Patterns of Candida Isolates: A Cross-Sectional Study From a Tertiary Care Hospital in South India
5
PubMed Central. High prevalence of candiduria due to non-albicans Candida species among diabetic patients: A matter of concern?
6
Clinical Infectious Diseases. Candida Urinary Tract Infections—Diagnosis
7
PubMed Central. Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study
8
PubMed Central. An evaluation of the management of asymptomatic catheter-associated bacteriuria and candiduria at The Ottawa Hospital
9
Oxford Academic. Candida Urinary Tract Infections—Treatment
10
PubMed Central. Outcomes of caspofungin use in the treatment of Candida-related urinary tract infections, a case series
11
International Journal of Infectious Diseases. Bladder irrigation with amphotericin B and fungal urinary tract infection–systematic review with meta-analysis
12
PubMed. Treatment of catheter-associated Candiduria with fluconazole irrigation
13
PubMed Central. Extensive Urinary Tract Fungal Bezoars Causing Anuria: A Case Report
14
PubMed Central. Candida Bezoars in Adults: Determining Optimal Management
15
PubMed. Candiduria in intensive care units: association with heavy colonization and candidaemia
16
PubMed. To treat or not to treat–critically ill patients with candiduria
17
PubMed Central. Outcomes Following Candiduria in Extremely Low Birth Weight Infants
18
Clinical Infectious Diseases. Predictors and Outcomes of Candiduria in Renal Transplant Recipients
19
PubMed Central. Performance of Multiplex PCR and β-1,3-D-Glucan Testing for the Diagnosis of Candidemia